Intra-Cellular Therapies Inc

NASDAQ:ITCI   3:59:58 PM EDT
40.35
-2.72 (-6.32%)
Products

Intra-Cellular Therapies Announces U.S. FDA Approval Of Caplyta (Lumateperone) For The Treatment Of Bipolar Depression In Adults

Published: 12/20/2021 11:58 GMT
Intra-Cellular Therapies Inc (ITCI) - Intra-cellular Therapies Announces U.S. FDA Approval of Caplyta® (lumateperone) for the Treatment of Bipolar Depression in Adults.
Intra-cellular - Boxed Warning on Caplyta Says Elderly Patients With Dementia-related Psychosis Treated With Antipsychotic Drugs Are at Higher Risk of Death.
Intra-cellular Therapies Inc - Boxed Warning on Caplyta Says It is Not Approved for Treatment of Patients With Dementia-related Psychosis.
Intra-cellular Therapies - Boxed Warning on Caplyta Says Safety and Effectiveness of Caplyta Have Not Been Established in Pediatric Patients.